UNSPSC 51123118: Pilsicainide hydrochloride

This classification denotes an antiarrhythmic agent with the molecular structure C17H24N2O.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 03C8I9296V chemically known as 1h-pyrrolizine-7a(5h)-acetamide, n-(2,6-dimethylphenyl)tetrahydro-, hydrochloride (1:1), but more commonly known as pilsicainide hydrochloride, which bears US NIH Compound Identifier 114817. European Medicines Agency schedules Pilsicainide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03822MIG.

Most nations, for tariff and trade purposes, schedule pilsicainide hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, PILSICAINIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCCC(C1NC(=O)CC23CCCN2CCC3)C.CL.

UNSPSC 51123118 Pilsicainide hydrochloride, a Commodity code, covers anti-arrhythmic pharmaceutical products used in emergency medical response and state healthcare administration. State and local governments procure anti-arrhythmic medications under this code primarily through two channels: direct purchase by municipal fire and rescue services for advanced life support protocols, and bulk procurement by state health agencies and cooperative purchasing alliances for distribution through pharmacy benefit programs and state facility networks. Issuing bodies include municipal fire departments, state health and human services commissions, and multistate cooperative purchasing organizations coordinating procurement on behalf of multiple state and local jurisdictions. The work involves sourcing branded or generic formulations meeting FDA requirements, cGMP certification, and DSCSA compliance, with vendors required to maintain expiration-date thresholds, arrange cold-chain logistics where applicable, and supply Safety Data Sheets compliant with OSHA Hazard Communication Standards.

Recent activity spans Florida, Texas, and Minnesota-led multistate networks. The City of Tampa Fire Rescue issued IFB 26P00188 in April 2026 for advanced life support medications including epinephrine, adenosine, diltiazem, and labetalol (response due April 8, 2026; estimated contract value $40,000.00), with a 5 percent bid discount for Small Local Business Enterprise participation. Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling potential future state-level competitive solicitation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products (response due March 26, 2026), requiring manufacturers to supply through three authorized wholesalers with pricing competitiveness weighted at 75 percent of evaluation and a two-year initial contract term. All three solicitations emphasize regulatory compliance, multi-location distribution capability, and vendor insurance and liability coverage thresholds.